Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias01:25

ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias

Arrhythmia is a condition characterized by an irregular heart rhythm, with ECG changes that differ based on its origin and nature. The types of arrhythmias discussed below include atrial, junctional, and ventricular arrhythmias.Atrial ArrhythmiasPremature Atrial Complexes (PACs): PACs are early atrial beats caused by stress, caffeine, alcohol, electrolyte imbalances, hypoxia, hyperthyroidism, or certain medications (e.g., bronchodilators and decongestants). The ECG shows early P waves with an...
Disturbances in Heart Rhythm01:29

Disturbances in Heart Rhythm

Arrhythmia or dysrhythmia refers to an abnormal heart rhythm caused by a defect in the heart's conduction system. It can cause the heart to beat irregularly, too quickly, or too slowly, leading to symptoms like chest pain, shortness of breath, and fainting. Factors such as stress, caffeine, alcohol, nicotine, cocaine, certain drugs, congenital defects, diseases, and electrolyte abnormalities can trigger arrhythmias.
Arrhythmias are categorized by their speed, rhythm, and origin. A slow heart...
Dysrhythmias IV: Characteristics of Bradyarrhythmias01:18

Dysrhythmias IV: Characteristics of Bradyarrhythmias

Bradyarrhythmias are cardiac rhythm disorders characterized by a slower-than-normal heart rate, typically defined as fewer than 60 beats per minute. Some of which are discussed here:Sinus BradycardiaSinus bradycardia presents a heart rate lower than 60 beats per minute, with a regular rhythm originating from the SA node. The ECG typically shows normal P waves preceding each QRS complex, a normal PR interval (0.12 to 0.20 seconds), and a normal QRS duration (0.06 to 0.10 seconds).First-Degree AV...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Potential Drug-Drug Interactions With Nirmatrelvir/Ritonavir Among Long-Term Care Facility Residents.

Journal of the American Medical Directors Association·2026
Same author

Impact of empiric potassium supplementation on mortality, sudden cardiac arrest and stroke in furosemide initiators.

British journal of clinical pharmacology·2026
Same author

Ambient Temperature and Psoriatic Arthritis Odds Among Patients With Psoriasis: A Cross-sectional Analysis.

Journal of psoriasis and psoriatic arthritis·2026
Same author

Clinician Perceptions of Therapeutic Inertia in Type 2 Diabetes Mellitus: A Qualitative Study.

Journal of the American College of Clinical Pharmacy : JACCP·2026
Same author

Gabapentin and Opioid Prescribing Trends among Adolescents Undergoing Common Procedures: A National Retrospective Cohort Study.

Anesthesiology·2026
Same author

Comparison of disease risk score methods to study treatment effect heterogeneity: a simulation study.

American journal of epidemiology·2026

Related Experiment Video

Updated: Jul 3, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Cisapride and ventricular arrhythmia.

Sean Hennessy1, Charles E Leonard, Craig Newcomb

  • 1Department of Biostatistics and Epidemiology, and Center for Education and Research on Therapeutics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6021, USA. hennessy@mail.med.upenn.edu

British Journal of Clinical Pharmacology
|July 30, 2008
PubMed
Summary
This summary is machine-generated.

Cisapride use significantly increases the risk of ventricular arrhythmia hospitalization, especially during the initial prescription period. Potentially arrhythmogenic CYP3A4 inhibitors also elevate risk, likely due to their own effects, not drug interaction.

More Related Videos

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Related Experiment Videos

Last Updated: Jul 3, 2026

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus
08:28

Methods for ECG Evaluation of Indicators of Cardiac Risk, and Susceptibility to Aconitine-induced Arrhythmias in Rats Following Status Epilepticus

Published on: April 5, 2011

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia
09:36

Dual-Dye Optical Mapping of Hearts from RyR2R2474S Knock-In Mice of Catecholaminergic Polymorphic Ventricular Tachycardia

Published on: December 22, 2023

Area of Science:

  • Cardiology
  • Pharmacology
  • Clinical Research

Background:

  • Cisapride is a prokinetic agent with known cardiac risks.
  • Ventricular arrhythmias pose a significant threat to patient safety.
  • Understanding drug interactions is crucial for safe medication use.

Purpose of the Study:

  • To investigate the association between cisapride and ventricular arrhythmia.
  • To determine the impact of cisapride dosage on arrhythmia risk.
  • To examine the role of CYP3A4 inhibitors in cisapride-associated arrhythmias.

Main Methods:

  • A nested case-control study design was employed.
  • Medicaid beneficiaries exposed to cisapride, metoclopramide, or proton pump inhibitors (PPIs) were analyzed.
  • Cases were identified by hospitalization for sudden cardiac death or ventricular arrhythmia.

Main Results:

  • Cisapride use was associated with a 2.10-fold increased odds of ventricular arrhythmia compared to PPIs.
  • This risk escalated to a 7.85-fold increase during the initial prescription period.
  • Potentially arrhythmogenic CYP3A4 inhibitors increased risk in both cisapride and PPI users.

Conclusions:

  • Cisapride is linked to a 2- to 3-fold higher risk of ventricular arrhythmia hospitalization.
  • The risk is substantially elevated (nearly 8-fold) early in treatment.
  • Arrhythmia risk with CYP3A4 inhibitors appears independent of cisapride interaction.